Ernexa Therapeutics IncERNA
Price$2.96

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $582K0.0% YoYTTM through 31 Mar 2026
Net Income -$14.1MTTM through 31 Mar 2026
Free Cash Flow -$7.1MTTM through 31 Mar 2026

Margins

Current
Gross Margin0.0%
Operating Margin-1,601.2%
Net Margin-2,419.9%

Returns

-205.3%ROE
-133.6%ROA

Balance Sheet Health

Debt / Equity0.06x
Current Ratio2.89x
Net Debt-$8.8Mnet cash position
Cash & Equivalents$9.2M

Quality Metrics

FCF Margin-1,219.9%

Dividend

No dividend
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.